Skip to main content
. 2022 May 3;2(3):316–323. doi: 10.21873/cdp.10111

Figure 4. Kaplan-Meyer analysis for recurrence-free survival according to HER2 expression in patients that receive adjuvant hormonal treatment with aromatase inhibitors (A) or tamoxifen (B). HER2: Human epidermal growth factor receptor-2; FU: follow-up.

Figure 4